查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球外阴阴道念珠菌病药物市场：市场规模-药物类别、给药途径、分销渠道、区域展望、竞争战略、细分市场预测 (-2032)
市场调查报告书
商品编码
1182446

全球外阴阴道念珠菌病药物市场：市场规模-药物类别、给药途径、分销渠道、区域展望、竞争战略、细分市场预测 (-2032)

Vulvovaginal Candidiasis Treatment Market Size- By Drug Class, By Route of Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 239 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

到 2032 年，全球外阴阴道念珠菌病药物市场规模预计将达到 16.2 亿美元，复合年增长率为 4.61%。

外阴阴道念珠菌病患病率上升、批准新药以满足未满足的需求以及政府和非营利组织为提高认识所做的努力是市场增长的主要驱动力。.

本报告考察了全球外阴阴道念珠菌病药物市场，涵盖市场动态、市场变量和前景、竞争格局、按药物类别划分的市场分析、给药途径、分销渠道和地区、公司概况等。我们提供信息。

内容

第一章介绍

  • 调查范围
  • 市场细分分析

第二章研究方法论

  • 调查数据来源
  • 市场规模估计
  • 数据三角测量

第 3 章执行摘要

第四章市场动态

  • 分析驱动因素、制约因素、机遇和挑战
    • 司机
    • 约束因素
    • 机会
    • 任务
  • COVID-19 对全球外阴阴道念珠菌病药物市场的影响

第五章市场变数与展望

  • SWOT 分析
    • 强度
    • 弱点
    • 机会
    • 威胁
  • PESTEL 分析
    • 政治形势
    • 经济状况
    • 社交情况
    • 技术
    • 环境状况
    • 法律状况
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手之间的敌对关係
  • 热图分析

第六章竞争格局

  • 全球治疗外阴阴道念珠菌病生产基地分布、销售区域、产品种类
  • 全球外阴阴道念珠菌病药物市场的併购、合作伙伴关係、产品发布和协作

第 7 章。全球外阴阴道念珠菌病药物市场：按药物类别（2019-2032，百万美元）

  • 克霉唑
  • 氟康唑
  • 酮康唑
  • 制霉菌素
  • 特比□芬
  • 特康唑
  • 其他

第 8 章。全球外阴阴道念珠菌病市场：按给药途径（2019-2032，百万美元）

  • 静脉注射
  • 口语
  • 本地

第 9 章。全球外阴阴道念珠菌病药物市场：按分销渠道（2019-2032，百万美元）

  • 医院药房
  • 在线药店
  • 零售药房

第 10 章全球外阴阴道念珠菌病药物市场：按地区（2019-2032，百万美元）

  • 全球各地区外阴阴道念珠菌病药物市场规模和市场份额（2019-2025 年）
  • 全球各地区外阴阴道念珠菌病药物市场规模和市场份额（2026 年至 2032 年）
  • 亚太地区
    • 澳大利亚
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 欧洲
    • 法国
    • 德国
    • 意大利
    • 西班牙
    • 英国
    • 其他欧洲
  • 中东和非洲
    • 沙特阿拉伯王国
    • 阿拉伯联合酋长国
    • 其他中东和非洲地区
  • 北美
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他南美洲

第11章公司简介

  • 安斯泰来製药公司
    • 公司简介
    • 财务展望
    • 产品概述
    • 最近的发展
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals
  • Grupo Ferrer International S.A.
  • Mycovia Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Scynexis, Inc.

第12章缩略语列表

第 13 章参考链接

第14章结论

第 15 章范围

简介目录
Product Code: PHAR2214

Global Vulvovaginal Candidiasis Treatment Market Overview:

According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.

The vagina and the tissues close to the vulva's opening are both impacted by vulvovaginal candidiasis, a yeast infection. Candida species are the culprit behind it. Intense itching, inflammation, a thick, white discharge, and other signs of the illness are present. A single dose of the antifungal medication or the use of antifungal creams can cure a mild infection, but more extensive infections need more time-consuming therapy. The size of the global market for vulvovaginal candidiasis treatments is anticipated to increase. An NCBI article claims that VVC is a frequent virus in women that affects millions of women annually all over the world. Rising illness burden, a strong growing pipeline with recent approvals of disease management medicines, and the introduction of novel pharmaceuticals like BREXAFEMME and VIVJOA are some of the main reasons propelling market growth.The rising prevalence of VVC disease, the approval of novel medications that can address unmet needs, and initiatives by the government and non-profit groups to raise awareness are some of the major drivers of business growth.

Impact of COVID-19 on the Global Vulvovaginal Candidiasis Treatment Market:

The global expansion of the new coronavirus has had a minor influence on the market for treating vulvovaginal candidiasis. Due to the increased prevalence of candidiasis among COVID-19 patients, there was a considerable demand for medications to treat vulvovaginal candidiasis. This is due to an increase in bloodstream infections and infections related with healthcare, particularly in patients who have been hospitalized to hospitals. The market for vulvovaginal candidiasis has quickly rebounded as a result of all these factors, and it is expected to keep expanding.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Class, By Route of Administration, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Grupo Ferrer International S.A., Mycovia Pharmaceuticals, Inc., Pfizer, Inc., Scynexis, Inc.

Global Vulvovaginal Candidiasis Treatment Market Segmentation:

  • By Drug Class: Based on the Drug Class, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Clotrimazole, Fluconazole, Ketoconazole, Nystatin, Terbinafine, Terconazole, Others.
  • By Route of Administration: Based on the Route of Administration, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Intravenous, Oral, Topical.
  • By Distribution Channel: Based on the Distribution Channel, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • By Region: The global industry was dominated by North America. The area is anticipated to continue to grow steadily during the projection period, maintaining its leadership position. High disease prevalence, rising patient awareness, rising healthcare costs, and the existence of significant players in the area can all be contributed to this dominance. The development of the regional market is also aided by new approvals, launches, and innovative government initiatives. Asia Pacific, on the other hand, is anticipated to experience the fastest growth rate during the anticipated years. The increased disease burden of VVC and rising testing rates are both responsible for the high growth rate. Positive developments include government healthcare coverage, increasing consumer awareness, and a desire to use medical services.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Vulvovaginal Candidiasis Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Vulvovaginal Candidiasis Treatment Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vulvovaginal Candidiasis Treatment Market

7. Global Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2019-2032 (USD Million)

  • 7.1 Clotrimazole
  • 7.2 Fluconazole
  • 7.3 Ketoconazole
  • 7.4 Nystatin
  • 7.5 Terbinafine
  • 7.6 Terconazole
  • 7.7 Others

8. Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2019-2032 (USD Million)

  • 8.1 Intravenous
  • 8.2 Oral
  • 8.3 Topical

9. Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

  • 9.1 Hospital Pharmacy
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy

10. Global Vulvovaginal Candidiasis TreatmentMarket, By Region, 2019-2032 (USD Million)

  • 10.1 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2019-2025)
  • 10.2 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2026-2032)
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Europe
    • 10.4.1 France
    • 10.4.2 Germany
    • 10.4.3 Italy
    • 10.4.4 Spain
    • 10.4.5 United Kingdom
    • 10.4.6 Rest of Europe
  • 10.5 Middle East & Africa
    • 10.5.1 Kingdom of Saudi Arabia
    • 10.5.2 United Arab Emirates
    • 10.5.3 Rest of Middle East & Africa
  • 10.6 North America
    • 10.6.1 Canada
    • 10.6.2 Mexico
    • 10.6.3 United States
  • 10.7 Latin America
    • 10.7.1 Argentina
    • 10.7.2 Brazil
    • 10.7.3 Rest of South America

11. Company Profiles

  • 11.1 Astellas Pharma Inc.
    • 11.1.1 Company details
    • 11.1.2 Financial outlook
    • 11.1.3 Product summary
    • 11.1.4 Recent developments
  • 11.2 Basilea Pharmaceutica Ltd.
    • 11.2.1 Company details
    • 11.2.2 Financial outlook
    • 11.2.3 Product summary
    • 11.2.4 Recent developments
  • 11.3 Bayer AG
    • 11.3.1 Company details
    • 11.3.2 Financial outlook
    • 11.3.3 Product summary
    • 11.3.4 Recent developments
  • 11.4 Bristol-Myers Squibb Company
    • 11.4.1 Company details
    • 11.4.2 Financial outlook
    • 11.4.3 Product summary
    • 11.4.4 Recent developments
  • 11.5 Cadila Pharmaceuticals
    • 11.5.1 Company details
    • 11.5.2 Financial outlook
    • 11.5.3 Product summary
    • 11.5.4 Recent developments
  • 11.6 Grupo Ferrer International S.A.
    • 11.6.1 Company details
    • 11.6.2 Financial outlook
    • 11.6.3 Product summary
    • 11.6.4 Recent developments
  • 11.7 Mycovia Pharmaceuticals, Inc.
    • 11.7.1 Company details
    • 11.7.2 Financial outlook
    • 11.7.3 Product summary
    • 11.7.4 Recent developments
  • 11.8 Pfizer, Inc.
    • 11.8.1 Company details
    • 11.8.2 Financial outlook
    • 11.8.3 Product summary
    • 11.8.4 Recent developments
  • 11.9 Scynexis, Inc.
    • 11.9.1 Company details
    • 11.9.2 Financial outlook
    • 11.9.3 Product summary
    • 11.9.4 Recent developments

12. List of Abbreviations

13. Reference Links

14. Conclusion

15. Research Scope